The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a
balance in internal environment (temperature, mood, and immune system) and energy input …

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range
of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms …

Background Almost a third of patients with epilepsy have a treatment-resistant form, which is
associated with severe morbidity and increased mortality. Cannabis-based treatments for …

As marijuana use becomes legal in some states, the dominant public opinion is that
marijuana is a harmless source of mood alteration. Although the harms associated with …

Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …

Cannabis, a genus of perennial indigenous plants is well known for its recreational and
medicinal activities. Cannabis and its derivatives have potential therapeutic activities to treat …

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a
promising candidate for the treatment of both somatic and psychiatric disorders. The aim of …

The purpose of this study was to investigate whether the anxiolytic effect of cannabidiol
(CBD) in humans follows the same pattern of an inverted U-shaped dose-effect curve …

Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis
sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response …